The Health Care M&A Monthly: Private Equity In The Middle Market-
Private Equity Firms Continue To Find Good Deals Email Editor Financial entities, such as REITS and private equity firms, continue to make their mark in the health care M&A market. During April, financial concerns were involved in 11 transactions, either as...The Health Care M&A Monthly: AstraZeneca Grabs MedImmune-$15.2 Billion Deal Is Largest Biotech Transaction Ever
Email Editor April’s M&A market produced the largest biotechnology deal ever seen. Britain’s AstraZeneca plc (NYSE: AZN) announced that it is buying MedImmune (NASDAQ: MEDI) for $58.00 per share, or $15.2 billion. In AZN’s sights are MEDI’s vaccine business and...The Health Care M&A Monthly: Schering-Plough Diversifies: Fred Hassan Buys Organon BioSciences For $15.8 Billion
Email Editor Last year, the Dutch chemical conglomerate Akzo Nobel, N.V. (AS: AKZO) announced its intention to divest Organon BioSciences, its pharmaceutical division, either through an outright sale or by floating the unit in an IPO. It has found a willing buyer in...The Health Care M&A Monthly: Pharma Captures Big Bucks –
Ten Deals Announced Worth A Combined $7.5 Billion Email Editor The Pharmaceutical sector generated 10 deals in February, worth a combined total of $7.5 billion. Two of the 10 were billion-dollar deals. The largest involves the $4.3 billion combination of Tanabe...The Health Care M&A Monthly: February’s Hospital M&A Market-
Triad Hospitals Privatized In $6.4 Billion Deal On Monday, March 19, Community Health Systems (NYSE: CYH) announced that it was taking advantage of the go-shop provision in the $6.4 billion deal to privatize Triad Hospitals (NYSE: TRH), discussed below, and would...Schedule a demo
Gain access to the best healthcare and long-term care investment intelligence, data, and analysis.
